Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 13 | 2026 | 279 | 2.660 |
Why?
|
| Hypoglycemic Agents | 11 | 2026 | 165 | 1.760 |
Why?
|
| Insulin | 5 | 2012 | 146 | 0.900 |
Why?
|
| Metformin | 3 | 2026 | 35 | 0.710 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 17 | 0.670 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 7 | 0.620 |
Why?
|
| Middle Aged | 13 | 2026 | 2108 | 0.600 |
Why?
|
| Adult | 12 | 2026 | 2113 | 0.560 |
Why?
|
| Humans | 26 | 2026 | 6794 | 0.560 |
Why?
|
| Male | 17 | 2026 | 3671 | 0.490 |
Why?
|
| Female | 16 | 2026 | 4060 | 0.490 |
Why?
|
| Glycated Hemoglobin A | 5 | 2021 | 65 | 0.480 |
Why?
|
| Cholesterol | 3 | 2013 | 37 | 0.460 |
Why?
|
| Minority Groups | 2 | 2012 | 63 | 0.450 |
Why?
|
| Aged | 8 | 2026 | 1539 | 0.440 |
Why?
|
| Insulin Resistance | 3 | 2012 | 74 | 0.440 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 22 | 0.390 |
Why?
|
| Thiazolidinediones | 2 | 2011 | 39 | 0.390 |
Why?
|
| Insurance, Health | 1 | 2013 | 26 | 0.390 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 21 | 0.390 |
Why?
|
| Treatment Outcome | 8 | 2025 | 500 | 0.380 |
Why?
|
| Poverty | 1 | 2012 | 64 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 72 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 153 | 0.350 |
Why?
|
| Triazoles | 1 | 2011 | 12 | 0.350 |
Why?
|
| Pyrazines | 1 | 2011 | 17 | 0.350 |
Why?
|
| Blood Glucose | 5 | 2026 | 188 | 0.340 |
Why?
|
| Insulin, Isophane | 1 | 2010 | 3 | 0.340 |
Why?
|
| Double-Blind Method | 6 | 2025 | 101 | 0.280 |
Why?
|
| Adolescent | 6 | 2013 | 869 | 0.270 |
Why?
|
| Cholesterol, LDL | 2 | 2006 | 35 | 0.250 |
Why?
|
| Hypoglycemia | 2 | 2025 | 30 | 0.250 |
Why?
|
| Lipids | 1 | 2006 | 35 | 0.250 |
Why?
|
| Atherosclerosis | 1 | 2006 | 39 | 0.240 |
Why?
|
| Amylin Receptor Agonists | 1 | 2025 | 1 | 0.240 |
Why?
|
| Anti-Obesity Agents | 1 | 2025 | 4 | 0.240 |
Why?
|
| Young Adult | 3 | 2013 | 567 | 0.230 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 3 | 0.220 |
Why?
|
| Phytotherapy | 1 | 2004 | 5 | 0.220 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 84 | 0.200 |
Why?
|
| Obesity | 1 | 2025 | 226 | 0.200 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 67 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 35 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2020 | 331 | 0.180 |
Why?
|
| Streptococcus pyogenes | 1 | 2001 | 2 | 0.170 |
Why?
|
| Shock, Septic | 1 | 2001 | 4 | 0.170 |
Why?
|
| Streptococcal Infections | 1 | 2001 | 3 | 0.170 |
Why?
|
| Influenza B virus | 2 | 2011 | 2 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 506 | 0.170 |
Why?
|
| Influenza, Human | 2 | 2011 | 18 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 172 | 0.160 |
Why?
|
| Glycemic Index | 1 | 2020 | 4 | 0.160 |
Why?
|
| Biomarkers | 2 | 2020 | 214 | 0.160 |
Why?
|
| Antimalarials | 1 | 2019 | 4 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2019 | 20 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 52 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2019 | 89 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 208 | 0.150 |
Why?
|
| Risk Factors | 3 | 2012 | 767 | 0.140 |
Why?
|
| Accelerometry | 1 | 2017 | 3 | 0.140 |
Why?
|
| Self Report | 1 | 2017 | 35 | 0.130 |
Why?
|
| United States | 3 | 2017 | 1019 | 0.130 |
Why?
|
| Exercise | 1 | 2017 | 55 | 0.130 |
Why?
|
| Weight Loss | 2 | 2025 | 35 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2025 | 155 | 0.110 |
Why?
|
| Testosterone | 2 | 2006 | 50 | 0.100 |
Why?
|
| Child, Preschool | 4 | 2011 | 258 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 66 | 0.100 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 11 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2012 | 28 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 42 | 0.100 |
Why?
|
| Perception | 1 | 2012 | 19 | 0.100 |
Why?
|
| Glucagon-Like Peptides | 2 | 2023 | 3 | 0.090 |
Why?
|
| Logistic Models | 1 | 2012 | 165 | 0.090 |
Why?
|
| Educational Status | 1 | 2012 | 61 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 145 | 0.090 |
Why?
|
| Antibodies, Antinuclear | 1 | 2011 | 3 | 0.090 |
Why?
|
| Sitagliptin Phosphate | 1 | 2011 | 6 | 0.090 |
Why?
|
| Los Angeles | 1 | 2012 | 321 | 0.090 |
Why?
|
| Smoking | 1 | 2012 | 86 | 0.090 |
Why?
|
| Mortality | 1 | 2011 | 43 | 0.090 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2011 | 1 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2011 | 3 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 2 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 11 | 0.080 |
Why?
|
| Cities | 1 | 2010 | 7 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 1 | 0.080 |
Why?
|
| Insulin, Long-Acting | 1 | 2010 | 14 | 0.080 |
Why?
|
| Weight Gain | 1 | 2010 | 28 | 0.080 |
Why?
|
| Insulin Glargine | 1 | 2010 | 15 | 0.080 |
Why?
|
| Nicotine | 1 | 2012 | 144 | 0.080 |
Why?
|
| African Americans | 1 | 2012 | 264 | 0.080 |
Why?
|
| Child | 3 | 2011 | 524 | 0.080 |
Why?
|
| Apolipoproteins B | 2 | 2006 | 6 | 0.070 |
Why?
|
| Cholesterol, HDL | 2 | 2006 | 23 | 0.070 |
Why?
|
| Triglycerides | 2 | 2006 | 58 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2010 | 681 | 0.070 |
Why?
|
| Demography | 1 | 2006 | 26 | 0.060 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 2 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2006 | 82 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 17 | 0.060 |
Why?
|
| Cytokines | 1 | 2006 | 80 | 0.060 |
Why?
|
| Oxadiazoles | 1 | 2025 | 1 | 0.060 |
Why?
|
| Fluorine Compounds | 1 | 2025 | 1 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 54 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 40 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2004 | 36 | 0.050 |
Why?
|
| Chromans | 1 | 2004 | 1 | 0.050 |
Why?
|
| Annexin A2 | 1 | 2004 | 1 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 8 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2004 | 13 | 0.050 |
Why?
|
| Adipocytes | 1 | 2004 | 31 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2023 | 7 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2023 | 1 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 90 | 0.050 |
Why?
|
| Quality of Life | 1 | 2004 | 184 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 11 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 2 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 10 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2001 | 11 | 0.040 |
Why?
|
| Taiwan | 2 | 2011 | 4 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2001 | 13 | 0.040 |
Why?
|
| HIV Infections | 1 | 2006 | 432 | 0.040 |
Why?
|
| Family | 1 | 2001 | 27 | 0.040 |
Why?
|
| Selenium | 1 | 2000 | 2 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2000 | 9 | 0.040 |
Why?
|
| Fructosamine | 1 | 2020 | 3 | 0.040 |
Why?
|
| Glycation End Products, Advanced | 1 | 2020 | 7 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 21 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2000 | 14 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 50 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 220 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 268 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 21 | 0.030 |
Why?
|
| Animals | 2 | 2012 | 1875 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2012 | 10 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 2012 | 6 | 0.020 |
Why?
|
| Biological Transport | 2 | 2004 | 22 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2012 | 40 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cause of Death | 1 | 2011 | 82 | 0.020 |
Why?
|
| Encephalomyelitis | 1 | 2011 | 1 | 0.020 |
Why?
|
| Mediastinal Emphysema | 1 | 2011 | 1 | 0.020 |
Why?
|
| Subcutaneous Emphysema | 1 | 2011 | 2 | 0.020 |
Why?
|
| Bronchi | 1 | 2011 | 3 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2011 | 3 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2010 | 1 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 285 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 75 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 321 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2006 | 5 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2006 | 20 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 13 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 118 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 147 | 0.010 |
Why?
|
| California | 1 | 2006 | 230 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 143 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 5 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 8 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 8 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 12 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 27 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 50 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 2002 | 1 | 0.010 |
Why?
|
| Triptorelin Pamoate | 1 | 2002 | 1 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2002 | 1 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 36 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 57 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 746 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 64 | 0.010 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 1 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cell Size | 1 | 2000 | 3 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 7 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 4 | 0.010 |
Why?
|
| Amino Acids | 1 | 2000 | 15 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 40 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 72 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2000 | 54 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 35 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 45 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 63 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 45 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 179 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 170 | 0.010 |
Why?
|